Baipus announced that it intends to invest 50 million yuan to participate in the investment of Tianjin Kang Orange Baien Equity Investment Fund Partnership (Limited Partnership), and the total amount of capital to be subscribed by the fund is 150 million yuan.
The chairman of the company is Chen Yiding. Mr. Chen Yiding, Chinese nationality, no right of permanent residence abroad, born in 1977, graduated from Shaanxi University of Science and Technology majoring in bioengineering, master's degree. From July 2003 to April 2007, he served as a cell culture researcher at China Cell Engineering Co., Ltd. From May 2007 to April 2009, he served as a technical sales expert and application development scientist in the Beijing office of Invitrogen Co., Ltd. in Hong Kong. From May 2009 to February 2011, he was the application scientist of bioprocess products at Thermo Fisher Biochemicals (Beijing) Co., Ltd.; Since March 2011, he has served as the chairman and general manager of the company (and the predecessor of Plypsys Co., Ltd.); Since January 2021, he has also served as the manager and executive director of Baisi Medical Diagnostic Technology (Beijing) Co., Ltd., a wholly-owned subsidiary of the company.
The above content is compiled by Securities Star based on public information, if you have any questions, please contact us.
![The "veteran" of the medical field intuitively resiliently strives to create the BodyVerse universe[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)